GlassScriptPhysician profile
Alexander Llinas
NPI 1194900365
$2,763.38
in general payments reported to CMS, 2019-2025
24 companies · $779 in 2025
The $779 reported for 2025 was more than what a typical Ophthalmology provider received nationally (typical 2025 total: $384).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $190 · 2020: $12.57 · 2021: $35.13 · 2022: $515 · 2023: $498 · 2024: $735 · 2025: $779.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,011.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,011.08 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Oyster Point Pharma, INC. | $655.20 | 2022-2025 | Tyrvaya |
| Tarsus Pharmaceuticals, INC. | $263.66 | 2024-2025 | Xdemvy |
| Bausch & Lomb Americas INC. | $237.45 | 2023-2025 | Miebo, Vyzulta, Xiidra |
| Sun Pharmaceutical Industries INC. | $234.58 | 2022-2025 | Cequa |
| Abbvie INC. | $214.79 | 2022-2025 | |
| Dompe US, INC. | $166.53 | 2022-2025 | Oxervate |
| Alcon Vision LLC | $155.25 | 2022-2025 | Tryptyr, Simbrinza, Rocklatan |
| Harrow Eye, LLC | $118.45 | 2024-2025 | Vevye |
| New World Medical,INC. | $103.75 | 2022 | |
| Amgen INC. | $85.64 | 2025 | Tepezza |
| Ani Pharmaceuticals, INC. | $84.73 | 2024 | Purified Cortrophin Gel |
| Biotissue Holdings INC. | $84.54 | 2019-2024 | |
| Sight Sciences, INC. | $75.33 | 2022-2023 | Tearcare System |
| Horizon Therapeutics Plc | $60.93 | 2019-2023 | Tepezza |
| Kala Pharmaceuticals, INC. | $40.24 | 2019 |
Show all 24 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Allergan, INC. | $31.61 | 2019-2022 | |
| Apellis Pharmaceuticals, INC. | $26.86 | 2025 | Syfovre |
| Bausch & Lomb, A Division of Bausch Health US, LLC | $24.59 | 2019-2020 | |
| Shire North American Group INC | $24.48 | 2019 | |
| Ocular Therapeutix, INC. | $17.25 | 2019 | |
| Ivantis, INC | $15.68 | 2021 | |
| Omeros Corporation | $14.54 | 2019 | |
| Eyevance Pharmaceuticals LLC | $13.95 | 2019 | |
| Aerie Pharmaceuticals, INC. | $13.35 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Alexander Llinas listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.